Data Insights

Loncastuximab tesirine by ADC Therapeutics for Follicular Lymphoma: Likelihood of Approval

Loncastuximab tesirine is under clinical development by ADC Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData,...

Data Insights

Loncastuximab tesirine by ADC Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval

Loncastuximab tesirine is under clinical development by ADC Therapeutics and currently in Phase II for Mantle Cell Lymphoma. According to...

Data Insights

ADCT-701 by ADC Therapeutics for Neuroendocrine Carcinoma: Likelihood of Approval

ADCT-701 is under clinical development by ADC Therapeutics and currently in Phase I for Neuroendocrine Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - ADCT-701 in Neuroendocrine Carcinoma

Data Insights

ADCT-701 by ADC Therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval

ADCT-701 is under clinical development by ADC Therapeutics and currently in Phase I for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - ADCT-701 in Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Data Insights

Risk adjusted net present value: What is the current valuation of ADC Therapeutics's ADCT-602?

ADCT-602 is a monoclonal antibody conjugated commercialized by ADC Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic...

Net Present Value Model: ADC Therapeutics SA's ADCT-602

Data Insights

ADCT-602 by ADC Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

ADCT-602 is under clinical development by ADC Therapeutics and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...

Likelihood of Approval and Phase Transition Success Rate Model - ADCT-602 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)